Pyxis Oncology Inc (PYXS) - News Archive

Elucidating the Mechanism of MICVO: Pyxis Oncology s Translational Breakthrough Amidst Competitive Challenges: Pyxis Oncology is at the forefront of unlocking next-generation therapies with their innovative approach to...

: The field of oncology is rapidly evolving with the development of new and innovative treatments. Pyxis Oncology is at the forefront, presenting promising preclinical results for its first-in-concept extracellular-targ...

Pyxis Oncology Initiates Promising New Trial for PYX-201, Expanding Potential in Solid Tumor TreatmentsIn a significant advancement in the field of oncology, Pyxis Oncology Inc. has announced the initiation of a Phase 1...

In recent developments, Pyxis Oncology Inc. has announced promising results from the preliminary clinical data of its candidate drug PYX-201 in a Phase 1 clinical trial. The findings indicate a confirmed overall respons...

Pyxis Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Boston, June 28, 2024 Pyxis Oncology, Inc. (Nasdaq: PYXS)Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company dedicated to deve...

Pyxis Oncology Inc., an emerging leader in the development of novel therapies for cancer, announced recently that it had received an $8 million payment from the sale of its royalty rights. This funding is expected to be...

Pyxis Oncology Announces $50 Million Private Placement, Potential Impact on Share ValueBoston-based Pyxis Oncology, a clinical stage company specializing in innovative therapeutics for difficult-to-treat cancers, has re...